NEOGNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends May 31

NEOGEN CORP

Financials through Q1 FY2027, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 7, 2026

$11.63−0.18 (-1.52%)

Close on Oct 19, 2026

Market cap: $2.54B
P/E (TTM): –
Dividend yield: –

Fundamental chart

Pick a measure to chart its full history

$870.40MFY2026, +11.7% a year since FY2012

Where these numbers come from

Parsed from the XBRL in Neogen's annual and quarterly filings with the SEC
Per-share figures adjusted for the 2-for-1 split on Jul 30, 2021
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is NEOG.

Revenue growth-0.3% · median -0.4%

Gross margin47.4% · median 62.4%

Operating margin-0.8% · median 19.4%

Net margin-6.3% · median 1.9%

Company	Revenue	Growth
IDXX	$4.55B	+12.8%
QDEL	$2.67B	-2.5%
LNTH	$1.56B	+2.3%
TECH	$1.22B	-0.4%
NEOG	$883.99M	-0.3%
MYGN	$806.60M	-3.2%

Company

Next earnings (est.): Jan 7, 2027, before open
Exchange: Nasdaq
Industry: In Vitro & In Vivo Diagnostic Substances
Fiscal year ends: May 31
Employees: 2,636
Held by institutions: 100.0%
Auditor: BDO USA, P.C.
SEC CIK: 711377

Advertisement
300 × 250